SCHEMBL2684178

SCHEMBL2684178

CCn1nc(-c2ccncc2)cc1NC(=O)C(Cc1ccc(F)c(F)c1)NCC(=O)O

nearest known ligand 0.64

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GPR142 Q7Z601 12/20 0.64
MAPT P10636 3/20 0.41
MEN1 O00255 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
MAPK1 P28482 1/20 0.41
KMT2A Q03164 1/20 0.41
KCNJ6 P48051 1/20 0.39
KCNJ5 P48544 1/20 0.39
KCNJ3 P48549 1/20 0.39
GRM5 P41594 1/20 0.38
TP53 P04637 1/20 0.37
RAB9A P51151 1/20 0.36
P2RY14 Q15391 1/20 0.35
NTRK1 P04629 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2684170 1.00 GPR142 (0.64) GPR142MAPTMEN1CYP1A2CYP2D6
SCHEMBL10284416 0.91 GPR142 (0.78) GPR142MAPTKCNJ6KCNJ5KCNJ3
SCHEMBL2684833 0.90 GPR142 (0.67) GPR142MAPTMEN1CYP1A2CYP2D6
SCHEMBL2684830 0.90 GPR142 (0.67) GPR142MAPTMEN1CYP1A2CYP2D6
SCHEMBL2684288 0.89 GPR142 (0.49) GPR142MAPTMEN1CYP1A2CYP2D6
Hydrochloric Acid SCHEMBL2685960 0.89 GPR142 (0.66) GPR142MAPTMEN1CYP1A2CYP2D6
Hydrochloric Acid SCHEMBL2685955 0.89 GPR142 (0.66) GPR142MAPTMEN1CYP1A2CYP2D6
SCHEMBL2684864 0.89 GPR142 (0.80) GPR142MAPTMEN1CYP1A2CYP2D6
SCHEMBL2684852 0.89 GPR142 (0.80) GPR142MAPTMEN1CYP1A2CYP2D6
SCHEMBL2684268 0.84 GPR142 (0.43) GPR142MAPTMEN1CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8785468-B2 Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions AMGEN INC. (US) 2014-07-22 US claimed
US-8785468-B2 Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions AMGEN INC. (US) 2014-07-22 US disclosed
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2012-05-10 US disclosed
WO-2010093849-A2 PHENYLALANINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2010-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS IAPP, INSR, AMY2A GPR142 2779/4885MAPT 4112/4885MEN1 3254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.